	=	5
<u></u>		283
匚		6
$\geq$ 1		_
0		
8	<u> </u>	U
0		

PTO/SB/05 (08-00)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. 30195-pa

First Inventor Coelho, P., et al
Apparatus and Method of
Title Preparation of Stable, Long

(Only for new nonprovisional applications under 37 CFR 1.53(b)) Express Mail Label No. EL217260257US

APPLICA	ATION ELEMENTS	ADDRESS TO: Box Patent Application
See MPEP chapter 600 con-	ceming utility patent application contents.	Washington, DC 20231
	orm (e.g., PTO/SB/17) duplicate for fee processing)	CD-ROM or CD-R in duplicate, large table or     Computer Program (Appendix)
2. XX Applicant claims s See 37 CFR 1.27	small entity status.	Nucleotide and/or Amino Acid Sequence Submission     (if applicable, all necessary)
3. XX Specification (preferred arrangement		a. Computer Readable Form (CRF)
	e to Related Applications	b. Specification Sequence Listing on:
	arding Fed sponsored R & D	i. ☐ CD-ROM or CD-R (2 copies); or
or a computer p	equence listing, a table, program listing appendix	ii.□ paper
- Background of - Brief Summary		c. Statements verifying identity of above copies
<ul> <li>Brief Description</li> </ul>	n of the Drawings (if filed)	ACCOMPANYING APPLICATION PARTS
- Detailed Descri - Claim(s)	ption	9. Assignment Papers (cover sheet & document(s))
- Abstract of the	Disclosure	10. 37 CFR 3.73(b) Statement (when there is an assignee) Power of Attorney
4. XX Drawing(s) (35 U	l.S.C. 113) [ Total Sheets 12]	11. English Translation Document (if applicable)
5. Oath or Declaration	[Total Pages 4]	12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
Conv from a	uted (original or copy) prior application (37 CFR 1.63 (d))	13. XX Preliminary Amendment
b. 🕰 (for continua	tion/divisional with Box 17 compléted)	14. XX Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
Signed sta	ION OF INVENTOR(S) tement attached deleting inventor(s)	15. Certified Copy of Priority Document(s) (if foreign priority is claimed)
	the prior application, see 37 CFR and 1.33(b).	16. XX Other: Letter to the
	Sheet. See 37 CFR 1.76	Draftsman
		the requisite information below and in a preliminary amendment,
or in an Application Data She	pet under 37 CFR 1.76:  Divisional Continuation-in-part (CIP)	of prior application No.: 09 , 129,988
Prior application information:	Robinson, H.	Group I Art Unit:
For CONTINUATION OR DIVISI	ONAL APPS only: The entire disclosure of the p	rior application, from which an oath or declaration is supplied under
The incorporation can only be	relied upon when a portion has been inadvertent	on or divisional application and is hereby incorporated by reference. tly omitted from the submitted application parts.
	18. CORRESPONDENC	CE ADDRESS
Customer Number or Bar Code Label  (Insert Customer No. or Affach bar code label here)  Or Correspondence address below		
Name	Bernhard Kreten	
Address	77 Cadillac Drive, S	uite 245
City	Sacramento Si	tate California Zip Code 95825
Country	United States / Teleph	one (916) 921-61\$1 <sub>Fax</sub>   921-9213
Name (Print/Type)	Bernhard Kreten	Registration No. (Attorney/Agent) 27,037
Signature	Jet 1	Date 11/9/2000
Burden Hour Statement: This form	is estimated to take 0.2 hours to complete. Time w	ill vary depending upon the needs of the individual case. Any comments on

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

### **CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10**

a . . .

Applicant:

Philip Henry Coelho, Phil Kingsley, Jim Brausch, James H. Godsey and Gail Rock

For:

Apparatus and Method of Preparation of Stable, Long Term Thrombin from Plasma and Thrombin Formed Thereby

Paper:

- 1. A Patent Application (Utility) (comprised of pages 1 through 20) (copy from a prior application);
- 2. A Utility Patent Application Transmittal;
- 3. A Fee Transmittal (original and one copy);
- 4. A Declaration for Patent Application (copy from a prior application);
- 5. A Verified Statement Claiming Small Entity Status (Independent Inventor) (copy from a prior application);
- 6. Twelve (12) sheets of drawing figures (comprised of figures 1 through 12) (copy from a prior application);
- 7. A Preliminary Amendment;
- 8. A Letter to the Draftsman;
- 9. Twelve (12) sheets of formal drawing figures (comprised of figures 1 through 12);
- 10. A Form PTO-1449 (including prior art copies); and
- 11. A check in the amount of \$435.00, \$355.00 of which reflects the government filing fee for utility patent, and \$80.00 of which is to cover the government fee for two (2) independent claims in excess of three.

I hereby certify that the above identified correspondence, which is attached, is being deposited with the United States Postal Service, Express Mail, Post Office to Addressee, mailing label #EL217260257US, in an envelope addressed to:

Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231

on November 10, 2000.

Ellen J. Tenud

(Signature)

November 10, 2000

(Date of Signature)

The state of the s

Name (Pnnt/Type)

Signature

PTO/SB/17 (08-00)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2000

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$) 4	43	5		0	0
--------	----	---	--	---	---

Complete if Known		
Application Number		
Filing Date		
First Named Inventor	Coelho, P., et al.	
Examiner Name		
Group Art Unit		
Attorney Docket No.	30195-pa	

METHOD OF PAYMENT (check one)	FEE CALCULATION (continued)		
The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:	3. ADDITIONAL FEES		
Deposit Fee Fee Fee Fee Fee Fee Fee Fee Fee Fe			
Account Number 11-1734	100 (b) 00 (b)	Pala	
Deposit Deposit IZ-not and	105 130 205 65 Surcharge - late filing fee or oath		
Account Bernhard Kreten	127 50 227 25 Surcharge - late provisional filing fee or cover sheet		
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	139 130 139 130 Non-English specification		
Applicant claims small entity status.	147 2,520 147 2,520 For filing a request for ex parte reexamination		
See 37 CFR 1.27	112 920* 112 920* Requesting publication of SIR prior to Examiner action		
2. X Payment Enclosed: X Check Credit card Order Other	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action		
FEE CALCULATION	115 110 215 55 Extension for reply within first month		
	116 380 216 190 Extension for reply within second month		
1. BASIC FILING FEE Large Entity Small Entity	117 870 217 435 Extension for reply within third month		
Fee Fee Fee Fee Description	118 1,360 218 680 Extension for reply within fourth month		
404 000 004 045 14777 077 4	128 1,850 228 925 Extension for reply within fifth month		
101 690 201 345 Utility filing fee 355.	119 300 219 150 Notice of Appeal		
107 480 207 240 Plant filing fee	120 300 220 150 Filing a brief in support of an appeal		
108 690 208 345 Reissue filing fee	121 260 221 130 Request for oral hearing		
114 150 214 75 Provisional filing fee	138 1,510 138 1,510 Petition to institute a public use proceeding		
	140 110 240 55 Petition to revive - unavoidable		
SUBTOTAL (1) (\$) 355.	141 1,210 241 605 Petition to revive - unintentional		
2. EXTRA CLAIM FEES	142 1,210 242 605 Utility issue fee (or reissue)		
Fee from  Ext <u>ra Claims below</u> Fee Paid	143 430 243 215 Design issue fee		
Total Claims 1 2 -20** = 0 X =	144 580 244 290 Plant issue fee		
Independent $5 - 3^{**} = 2 \times 40 = 80$	122 130 122 130 Petitions to the Commissioner		
Multiple Dependent =	123 50 123 50 Petitions related to provisional applications	$\dashv$	
**or number previously paid, if greater; For Reissues, see below	126 240 126 240 Submission of Information Disclosure Stmt		
Large Entity Small Entity Fee Fee Fee Fee Description Code (\$) Code (\$)	581 40 581 40 Recording each patent assignment per property (times number of properties)		
103 18 203 9 Claims in excess of 20	146 690 246 345 Filing a submission after final rejection (37 CFR § 1.129(a))		
102 78 202 39 Independent claims in excess of 3  104 260 204 130 Multiple dependent claim, if not paid	149 690 249 345 For each additional invention to be		
104 260 204 130 Multiple dependent claim, if not paid 109 78 209 39 ** Reissue independent claims	examined (37 CFR § 1.129(b))		
over original patent	179 690 279 345 Request for Continued Examination (RCE)		
110 18 210 9 ** Reissue claims in excess of 20	169 900 169 900 Request for expedited examination of a design application		
and over original patent Other fee (specify)			
SUBTOTAL (2) (\$) 80. Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0.			
SUBTOTAL (2) (\$) 80.			
SUBMITTED BY			

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Registration No.

27,037

Telephone

Date

(916) 921-61 11/9/2000

Applicant: Philip Henry Coell	o, Phil Kingsley, Jim Brau	isch, James H. Godsey, Gail Rock
	988 Atı	torney's Docket No.: 28182-pa
Filed: August 5, 1998		
For: <u>Apparatus and Method of</u> <u>Thrombin Formed Thereby</u>	Preparation of Stable, Lon	g Term Thrombin from Plasma and
VERIFIED STATEME STATUS (37 CFR	NT (DECLARATION) CLA 1.9(f) and 1.27(b)) - INDE	AIMING SMALL ENTITY PENDENT INVENTOR
As a below named inventor, I defined in 37 CFR 1.9(c) for pu Title 35, United States Code, to	rposes of paying reduced t	alify as an independent inventor as fees under section 41 (a) and (b) of described in:
the specification filed he XX application serial no.: patent no	09/129,988 , filed A	ugust 5, 1998
I have not assigned, granted, cor or law to assign, grant, convey could not be classified as an ir	nveyed or licensed and am or license, any rights in ndependent inventor under concern which would not o	under no obligation under contract the invention to any person who 37 CFR 1.9(c) if that person had qualify as a small business concern
Each person, concern or organiz or am under an obligation under in the invention is listed below:	contract or law to assign	gned, granted, conveyed, or licensed grant, convey or license any rights
no such person, concern, XX person, concerns or organ	or organization. nizations listed below*	
*NOTE: Separate verified organization having right (37 CFR 1.27)	statements are required f s to the invention averrin	for each named person, concern or g to their status as small entities
FULL NAME ThermoGenesis	Corp.	
ADDRESS 3146 Gold Camp Dri	ve, Rancho Cordova, Califor	nia 95670
[ ] individual	[X] small business concern	[ ] nonprofit organization
status resulting in loss of entitle	ement to small entity statu fee due after the date on y	ent, notification of any change in is prior to paying, the earliest of which status as a small entity is no
statements made on information statements were made with the lare punishable by fine or impriso States Code, and that such wi	and belief are believed to cnowledge that willful false nment, or both, under sect llful false statements ma	n knowledge are true and that all be true; and further that these statements and the like so made ion 1001 of Title 18 of the United y jeopardize the validity of the which this verified statement is
Philip Menry Coelho	Phil Kingsley	Jim Brausch
NAME OF INVENTOR	NAME OF INVENTOR	
Signature of Inventor	Signature of Inventor	Signature of Inventor
10/6/98	10/6/18	10/4/48
Date / /	Date	Date

James H. Godsey	Gail Rock	
NAME OF INVENTOR	NAME OF INVENTOR	NAME OF INVENTOR
Signature of Inventor  10-6-98	Signature of Inventor	Signature of Inventor
Date	Date	Date

James H. Godsey	Gail Rock	
NAME OF INVENTOR	NAME OF INVENTOR	NAME OF INVENTOR
Signature of Inventor	Signature of Inventor	Signature of Inventor
Date	Date 12 Oct 98	Date

#### UNITED STATES PATENT AND TRADEMARK OFFICE

**APPLICANT:** Coelho, P., et al.

**FOR:** Apparatus and Method of

Preparation of Stable, Long Term Thrombin From Plasma and Thrombin Formed Thereby

To: Commissioner of Patents and Trademarks Washington, DC 20231

### **PRELIMINARY AMENDMENT**

Sir:

Before a first Office Action on the merits, kindly enter the following amendments:

#### **IN THE SPECIFICATION**

Page 2, line 1, kindly insert the paragraph -- This application is a division of application serial number 09/129,988, filed August 5, 1998, status: pending. -- after "Field of the Invention".

Page 11, line 15, kindly change "CaCL<sub>2</sub>" to -- CaCl<sub>2</sub> --.

Page 11, line 17, kindly change "CaCL<sub>2</sub>" to -- CaCl<sub>2</sub> --.

Page 11, line 24, kindly change "CaCL<sub>2</sub>" to -- CaCl<sub>2</sub> --.

Page 12, line 7, kindly change "CaCL<sub>2</sub>" to -- CaCl<sub>2</sub> --.

Page 13, line 10, kindly change "fluids" to --fluid's--.

## **IN THE CLAIMS**

Kindly cancel claim 13 without prejudice or disclaimer as to its content.

///

# **Kindly Modify the Claims as Follows:**

Claim 4, line 1, kindly change "includes" to -- occurs by --.

Claim 4, line 2, kindly change "CaCL<sub>2</sub>" to -- CaCl<sub>2</sub> --.

Claim 6, line 1, kindly insert -- altering the clotting time, yielding -- after "wherein".

Claim 10, line 1, kindly insert -- thrombin -- after "A".

Claim 10, line 1, kindly delete -- for extracting thrombin from plasma -- after "composition".

Claim 12, line 3, kindly insert -- only -- after "adding".

# **Kindly Amend the Claims as Follows:**

Claim 1 (amended) - A method for generating [autologous] thrombin from <u>a</u> sole donor or a patient, the steps including:

obtaining a blood product from the patient;

sequestering plasma from the product;

maintaining the plasma undiluted and unprocessed;

enriching the prothrombin in a [plasma] fraction of the undiluted, unprocessed plasma;

converting the prothrombin to thrombin, and

filtering particulate from the thrombin.

Claim 3 (amended) - The method of claim 2 [including] wherein the enriching step occurs by adding ethanol to enrich the prothrombin in a plasma fraction.

Claim 8 - (amended) A method for producing autologous thrombin which is stable for more than 15 minutes, the steps including:

sequestering pro[-]thrombin from plasma <u>using ethanol</u> and converting the pro[-]thrombin to thrombin <u>by adding calcium ions</u>.

Claim 9 - (amended) Autologous thrombin which provides fast clotting of less than five seconds which is stable for more than 15 minutes.

# **REMARKS**

This Preliminary Amendment is provided before receipt of any substantive Office Action on the merits in this case and is provided to rectify various minor typographical inexactitudes and to present amended claims for the Examiner's kind consideration. No new matter has been presented.

In view of the foregoing, it is respectfully requested that the Examiner enter these amendments into this case.

Dated: November 9, 2000

Respectfully Submitted:

BERNHARD KRETEN Applicant's Attorney Telephone (916) 921-6181 Registration No.: 27,037

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE <a href="https://doi.org/10.1007/journal-no.1

Apparatus and Method of Preparation of Stable, Long Term Thrombin from Plasma and Thrombin Formed Thereby

# **FIELD OF THE INVENTION**

The following invention relates generally to the preparation of thrombin enzyme from a given unit of plasma, which is sufficiently stable that it provides rapid clotting of a fibrinogen-rich solution of clotting and adhesive proteins for more than six hours.

## **BACKGROUND OF THE INVENTION**

Formulation of a fibrin sealant mimics the last step of the coagulation cascade wherein the enzyme thrombin cleaves fibrinogen which is then cross-linked into a semi-rigid or flexible fibrin clot. This fibrin clot adheres to wound sites, forming a barrier to fluid leaks and generates adhesion between tissues, while providing hemostatic and healing properties to the treated site.

Presently marketed, applicant's CryoSeal™ system is a device which harvests cryoprecipitated, concentrated clotting and adhesive proteins, including fibrinogen and Factor XIII from a donor's plasma in approximately one hour. The one hour cryoprecipitation harvesting, provided by the CryoSeal™ system, compared to the 1 to 2 day cryoprecipitation process routinely practiced in Blood Banks, means that CryoSeal™ harvesting of clotting and adhesive proteins can occur right in the perioperative theater with the patient close by, thereby avoiding the need to initiate the process days in advance.

These CryoSeal<sup>TM</sup> harvested clotting and adhesive proteins, when combined with bovine or human thrombin, forms a biological glue useful for surgical hemostasis and tissue adhesion. Commercially available thrombin, however, is generally sourced from bovine or human plasma pools, so the patient would still be at risk of negative immune reactions or contamination by infectious blood born viruses and, possibly Crutzfeld-Jacobs Disease (CJD) or new variants of CJD (NVCJD). An advantage of the CryoSeal<sup>TM</sup> cryoprecipitation invention is that the harvested clotting and adhesive proteins sourced from the patient's own blood eliminates the risk of contamination by infectious blood-borne disease when these clotting and adhesive proteins are topically applied to the patient's surgical wound sites.

It has long been understood, however, that the safest condition for a surgical patient would result from a two component biological sealant preparation in which the thrombin component would be harvested from the same donor in which the clotting and adhesive protein component was harvested - forming a fully autologous biological sealant or glue.

For instance, Cederholm-Williams PCT Patent (WO94/00566 - 6 January 1994) clearly describes an improved fibrin glue in which the thrombin component whose preparation method, - adjusting the ionic strength of the blood and pH of the plasma to cause precipitation of a thrombin component for later resolubalization - was described therein, would be combined with a fibrinogen component also sourced from the plasma of the same donor. These steps are so time consuming they become impractical for use in the perioperative theater where processing times should be less than one hour.

Three years later, in 1997, Hirsh, et al. (U.S. Patent No. 5,643,192) follows the lead of Cederholm-Williams by also teaching a method of preparing fibrin glue in which both the fibrinogen and thrombin components of a fibrin glue are sourced from the same donor's plasma. The Hirsh patent describes a method of preparing thrombin in which the fibrinogen in the plasma is first precipitated to prepare a supernatant and then clotting the residual fibrinogen in the supernatant which is different than the method taught by Cederholm-Williams, but does not result in a commercially useful thrombin in that (see figure 1 of Hirsh, et al.) the thrombin provides clotting speeds of five seconds or less for only 4 minutes, and less than 10 seconds for only 47 minutes.

These clotting speeds are unsuitable to the needs of surgeons who could not plan their entire surgeries around the limitations of the Hirsh, et al. fibrin glue.

[Patent Application - 28182-pa - Page 4]

Surgeons predominately require a fast acting clotting time (< 5 seconds) for hemostasis and tissue sealing or adhesion. Slow clotting biological glues (> 5 seconds) will often be transported away from the wound site by oozing and bleeding before they can perform their function. A surgeon utilizing the Hirsh fibrin glue would be required to arrange his surgery so that the hemostasis and tissue sealing intended for treatment with the Hirsh fibrin glue would occur within the 4 minute window where the clotting time was less than 5 seconds, making the Hirsh invention totally impractical for most surgeries which predominantly require rapid hemostasis and tissue adhesion throughout the surgery, the time span of which could extend to six hours.

The following prior art reflects the state of the art of which applicant is aware and is included herewith to discharge applicant's acknowledged duty to disclose relevant prior art. It is stipulated, however, that none of these references teach singly nor render obvious when considered in any conceivable combination the nexus of the instant invention as disclosed in greater detail hereinafter and as particularly claimed.

#### **U.S. PATENT DOCUMENTS**

PATENT NO.	ISSUE DATE	<u>INVENTOR</u>
5,648,265 5,510,102 5,585,007 5,605,887 5,614,204 5,631,019 5,643,192	July 15, 1997 April 4, 1996 December 17, 1996 February 25, 1997 March 25, 1997 May 20, 1997 July 1, 1997	Epstein Cochrum Antanavich, et al. Pines, et al. Cochrum Marx Hirsh, et al.

## **FOREIGN PATENT DOCUMENTS**

PATENT NO. <u>ISSUE DATE</u> <u>INVENTOR</u>

[Patent Application - 28182-pa - Page 5]

WO 94/00566 EU 0 592 242 A1

January 6, 1994 April 13, 1994 Cederholm-Williams, et al. E.R. Squibb & Sons

The other prior art listed above, not all of which are specifically discussed catalog the prior art of which the applicant is aware. These undiscussed references diverge even more starkly from the instant invention specifically distinguished below.

# **SUMMARY OF THE INVENTION**

The instant invention addresses the long felt need for a simple, practical, fast method of preparing stable human thrombin from a donor's blood, which will provide fast clots (< 5 seconds) throughout a lengthy surgery (e.g. six hours) to combine with the clotting and adhesive proteins harvested and concentrated from the same unit of blood to form a biological sealant with no patient exposure to microbial or possible CJD or NVCJD contaminations. Previous works in the field (Hirsch, et al.) exemplified a thrombin with minimal stability in that the thrombin achieved rapid clotting of fibrinogen (i.e., less than 5 seconds) during only a very narrow four to five minute time period, totally impractical for the broad range of surgeries.

The present invention provides a stable thrombin enzyme which can cause precise, repeatable fast or slow polymerization of clotting and adhesive proteins over a duration of up to six hours - throughout even a long surgery. Further, the use of clotting and adhesive proteins and thrombin all sourced from a single donor will eliminate various disease risks posed from the use of commercial fibrin glues where the fibrinogen is sourced from plasma pooled from thousands of donors and the thrombin is either sourced from a similar pool of human plasma or of bovine origin. The speed and simplicity of the production of stable thrombin by use of this invention allows it to be prepared just prior to or during operative procedures and it will provide fast clotting throughout even the longest surgeries. The thrombin produced by this invention can be diluted in saline to provide precise, slower clotting times thereby allowing any preferred time from less than four seconds to longer than 2 minutes.

The procedure of the invention is comprised of three steps, the first two of which should occur at the same time:

- 1. Preparing a fraction enriched in prothrombin by use of Ethanol to substantially enhance the concentration of prothrombin and at the same time remove or denature naturally occurring ingredients within plasma, such as Thrombinodulin and Antithrombin III which can bind to, block, interfere with or inhibit prothrombin or its subsequent activation to long-term functional thrombin.
- 2. Adding calcium ions to the enriched prothrombin solution and briefly agitating the solution to convert the pro-thrombin to stable, long term thrombin.
- 3. Expressing the thrombin solution through a filter to remove particulate matter which would prevent spraying the thrombin through a small orifice or expressing the thrombin through a thin tube onto a wound site.

## **OBJECTS OF THE INVENTION**

Accordingly, it is a primary object of the present invention to provide a new and novel apparatus and method to derive fast acting, stable autologous thrombin from the donor's plasma.

It is a further object of the present invention to provide thrombin as characterized above which has a shelf life longer than most associated surgical procedures.

It is a further object of the present invention to provide thrombin as characterized above in which the clotting time can be predictably lengthened at will through dilution with saline.

It is a further object of the present invention to provide thrombin as characterized above which has simple preparatory procedures.

It is a further object of the present invention to provide a method for producing thrombin as characterized above which has a process time of less than thirty minutes.

It is a further object of the present invention to provide thrombin which can be sprayed through small orifices or expressed through thin tubes.

Viewed from a first vantage point it is the object of the present invention to provide a novel and practical method for producing stable human thrombin from a prothrombin fraction which has been substantially enriched by ethanol fractionation to increase the prothrombin concentration and at the same time remove contaminating proteins. The addition of calcium chloride to the enriched prothrombin converts prothrombin to thrombin. From the same sole donor plasma, clotting and adhesive proteins are simultaneously obtained by other means to comprise the second component necessary for the autologous biological sealant.

[Patent Application - 28182-pa - Page 9]

The present invention provides a method and apparatus that produces thrombin which is sufficiently stable that it can provide less-than-5-second clots for up to six hours, substantially more stable than demonstrated in all prior art. Further, the clot time can be modified at will through dilution with saline.

The present invention further provides an efficient method of preparation. Improved cryoprecipitation of clotting and adhesive proteins through the CryoSeal™ invention requires less than one hour. In this same time frame, the autologous human thrombin component can be manufactured with minimal materials and methods from the same source plasma. Both of the biological components of the biological glue are easily combined in a surgical setting, administered to the very same donor patient, and the resultant clotting provides hemostasis or tissue adhesion at the wound site.

The present invention additionally provides a method for sterile production of both components of the biological glue. The improved sterile manufacturing described herein provides a final product that is essentially free of contamination by non autologous microbes.

These and other objects will be made manifest when considering the following detailed specification when taken in conjunction with the appended drawing figures.

# **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a perspective view of an apparatus for sequestering prothrombin from plasma, processing the prothrombin into thrombin and taking the plasma not relegated towards the prothrombin and extracting clotting and adhesive proteins therefrom.

Figure 2 is a sectional view of the thrombin processing unit where plasma is being admitted into a mixing syringe.

Figure 3 is a view similar to figure 2 in which the processing reagents are directed to the mixing syringe for processing the plasma into prothrombin and then thrombin.

Figure 4 is a view similar to figures 2 and 3 where the thrombin is directed to a dispensing syringe after have first been filtered for particulate matter which could interfere with the thrombin being sprayed through a small orifice or expressed through a thin tube.

Figure 5 is a chart illustrating the effect of various ETOH concentrations in the final volume on the life span of fast clotting thrombin when the  $CaCL_2$  is held constant at 0.023  $\mu m$ .

Figure 6 is a chart illustrating the effect of various  $CaCL_2$  concentrations in the final volume on the life span of fast clotting thrombin when the ETOH concentration is held constant at 13.6%.

Figure 7 is a chart illustrating that the processing of the thrombin should occur in a glass syringe for a fast clotting preparation.

Figure 8 is a chart describing the contaminating proteins removed from the enriched thrombin fraction after mixture with ETOH, (13.6% in final volume) and  $CaCL_2$  (.023  $\mu m$  in final volume) and filtered for particulate matter.

[Patent Application - 28182-pa - Page 11]

Figure 9 is a view showing the life span of optimized thrombin preparation for fast clotting.

Figure 10 is a view showing the life span of optimized thrombin preparation diluted at 1:15 with sterile saline for slow clotting.

Figure 11 is a chart illustrating the conversion/activation period required for the enrichment of a prothrombin fraction and its conversion to stable thrombin by mixture with a precise solution of ETOH and CaCL<sub>2</sub>.

Figure 12 is a chart illustrating thrombin (Bovine) concentrations (activity) as it relates to speed of clotting.

#### **DESCRIPTION OF PREFERRED EMBODIMENTS**

Referring to the drawings, wherein like elements denote like parts throughout, reference numeral 10 is directed to the processing set according to the present invention and shown in figure 1.

In its essence, the processing set 10 includes a fluid receiving system 20 which communicates with both a thrombin processing unit 40 and a clotting and adhesive proteins processing unit 60.

More particularly, the fluid receiving system 20 includes an inlet 2 communicating with tubing 4 through which plasma will enter the processing units 40, 60. The conduit 4 has a stop valve 6 which can occlude the tubing 4 preventing fluids through passage. The tubing 4 communicates through a T fitting 8 to divide plasma into two branches, a first branch 12 which leads to the thrombin processing unit 40 and a second branch 14 leading to the clotting and adhesive proteins processing unit 60.

Since it is preferred that the blood product admitted to the inlet 2 be plasma, the whole blood is first processed either by filtering, centrifugation, or another means of settling to remove the heavier red blood cells from the blood products, leaving plasma therebeyond for use in the figure 1 device. The plasma required for the thrombin processing unit is preferably 8 ml. so that the final volume of concentrated thrombin matches a typical yield of cryoprecipitated clotting and adhesive proteins from the clotting and adhesive proteins processing unit 60. Referring to figure 2, a sealed bag 16 overlies the thrombin processing unit 40 to provide sterility until the thrombin storage syringe is introduced into a sterile surgical field. Prior to that, the thrombin processing unit is operated as shown in figure 2 within the sealed bag which is flexible and sized to preferably permit the

[Patent Application - 28182-pa - Page 13]

movement of the syringes' plungers from the exterior of the bag. Fluid from the first branch 12 passes beyond a coupling 18 and into a manifold 22. The manifold 22 is equipped with a valve 24 that initially is directed to a mixing syringe 26 preferably formed from glass and capable of receiving a volume as great as 15 ml. The mixing syringe 26 includes a plunger 28, which when moved in the direction of the arrow A, draws the plasma from the passageway 12 and into the interior of the mixing syringe 26.

Referring to figure 3, the valve 24 is reoriented so that access can be gained between the mixing syringe 26 and the reagents found in ampoules 32, 34, each of which are operatively connected to the manifold 22 via a Y coupling 36 shown in figure 1. Access to the interior of either ampoule 32 or 34 can be had by squeezing the ampoule to rupture a frangible diaphragm. Alternatively, the intake 38 which receives the ampoule can be provided with a hollow spike which penetrates the diaphragm. In either event, the contents of both of the ampoules 32, 34 are received in the mixing syringe 26 by further retraction of the plunger 28 along the arrow A shown in figure 3. A first ampoule 32 is preferably provided with 2 ml. of ethanol providing an ETOH concentration in the final volume of 13.6% and the second ampoule 34 is preferably provided with 1 ml. calcium chloride providing a concentration in the final volume of  $.023\mu m$ . Alternatively, these reagents contained within the two ampoules 32, 34 can be premixed into a single ampoule and dispensed simultaneously. In one form of the invention, it is possible to introduce the ethanol first, then agitate the mixing syringe 26 and then follow with the calcium chloride, but the introduction of both simultaneously to the plasma are optimally combined, followed by brief agitation.

Once the ethanol and calcium chloride have been introduced into the mixing syringe 26, the valve 24 is reoriented so that the mixing syringe 26 is isolated. The contents are briefly agitated and allowed to incubate for about 20 minutes. Prior to pushing the contents out of the mixing syringe 26, the valve 24 is reoriented as shown in figure 4 after which the plunger 28 is moved in the direction of the arrow B of figure 4. Because the valve 24 is now set to allow communication to the thrombin dispensing syringe 42, the contents within the mixing syringe 26 will be transferred from the mixing syringe 26 to the dispensing syringe 42. More specifically, the manifold 22 includes a recess within which a filter 44 is provided in the flow path between the mixing syringe 26 and the thrombin dispensing syringe 42. Particulate matter will be retained within the filter 44 prior to delivery of the thrombin to the dispensing syringe 42. Note that as fluid enters the dispensing syringe 42, the dispensing syringe plunger 46 moves in a direction opposite arrow B.

Referring back to figure 1, attention is now directed to the clotting and adhesive protein processing unit 60. All of the plasma not diverted to the thrombin processing unit 40 is admitted to an interior chamber 62 of the clotting and adhesive protein processing unit 60. The clotting and adhesive protein processing unit 60 is manipulated by heat exchange and rotation so that all clotting and adhesive proteins extracted from the plasma will sediment at a nose 64 of the bag 62 for subsequent extraction by means of a clotting and adhesive protein dispensing syringe 66 contained in a sterile pouch 68. Once the thrombin has been loaded into the dispensing syringe 42, and the clotting and adhesive proteins have been loaded into the clotting and adhesive dispensing syringe 66, the two syringes can be decoupled from the processing set 10 and ganged together for spraying or line and dot

application. Mixing the thrombin with the clotting and adhesive proteins forms the biological glue.

Both dispensing syringes should be stored at or below 4°C prior to usage.

Turning to figure 5, a graph is shown which illustrates how ethanol concentrations alter the life span of fast clotting thrombin where the calcium chloride content is held constant at point .023 µm. Note that at approximately 13:6% ethanol, its life span is shown to have been optimized and extend at least 240 minutes while its clotting time is substantially constant at under 5 seconds. The range between 8% and 18%, however, has utility.

Figure 6 varies the calcium chloride concentration in the thrombin while the ethanol is held constant at 13.6%. As shown, the thrombin life span where the calcium chloride concentration is at .023  $\mu m$  of 250 mM calcium chloride appears optimized and extends to 360 minutes while maintaining a clot time under 5 seconds. The range between .011 $\mu m$  of 125mM and .045 $\mu m$  of 500mM, however, has utility.

Figure 7 reflects the differences in processing the thrombin where the thrombin mixing syringe 26 is formed from glass versus plastic. As can be shown, the speed of clotting is held to close to 5 seconds or less with a life span of 60 to 240 minutes in glass.

Figure 8 reflects the effect of using ethanol at 13.6% and calcium chloride at .023 µm to reduce proteins which alter the clot time of the thrombin as compared to the original plasma. As can be seen in this graph, the major interfering proteins are so efficiently removed, that the clotting time of the thrombin is not only enhanced, but held substantially stable and constant.

Figure 9 shows in greater detail than that which is shown in figures 5 and 6 regarding the measured clot time as a function of life span for the optimized thrombin preparation, having been treated by 13.6% ethanol and .023  $\mu$ m calcium chloride. As shown, the life span extends to 360 minutes and the clot time varies from 3 to 4 seconds.

Figure 10 shows the effect of saline solution of the thrombin preparation optimized as in figure 9 with an ethanol concentration of 13.6% and a calcium chloride concentration of .023 µm as a function of life span. When the thrombin has been diluted 1 to 1.5 with saline, the clot time has been extended from just above 20 seconds to just less than 30 seconds, and has a life span of up to 150 minutes.

Referring to figure 11, there shown is the benefit in allowing the thrombin contained in the mixing syringe 26 to reside therein after agitation for almost 20 minutes in order to assure the effectiveness of the filtration step in removing particulate matter for subsequent utilization. The time span for conversation and activation allows enough particulate matter to be removed by the filter to optimize the use of the thrombin later in a narrow orificed dispenser, such as a sprayer or expressing through a thin tube.

Figure 12 provides a prior art comparison of the activity of thrombin sourced from Bovine blood plasma as it relates to the speed of clotting, showing that autologous thrombin derived from this invention provides a clotting speed equivalent to 100 iu/ml of Bovine thrombin.

Moreover, having thus described the invention, it should be apparent that numerous structural modifications and adaptations may be resorted to without departing from the scope and fair meaning of the instant invention as set forth hereinabove and as described hereinableow by the claims.

[Patent Application - 28182-pa - Page 17]

#### **CLAIMS**

I Claim:

Claim 1 - A method for generating autologous thrombin from a patient, the steps including:

obtaining a blood product from the patient; sequestering plasma from the product; enriching the prothrombin in a plasma fraction; converting the prothrombin to thrombin, and filtering particulate from the thrombin.

- Claim 2 The method of claim 1 further including the step of altering the clotting time.
- Claim 3 The method of claim 2 including adding ethanol to enrich the prothrombin in a plasma fraction.
- Claim 4 The method of claim 3 wherein the converting step includes adding  $C_a CL_2$ .
- Claim 5 The method of claim 4 including centrifuging the blood product for obtaining plasma.
- Claim 6 The method of claim 2 wherein a predictable clotting time extension occurs through diluting the thrombin with saline.
- Claim 7 The method of claim 6 including filtering the plasma by weight size and protein binding.
- Claim 8 A method for producing autologous thrombin which is stable for more than 15 minutes, the steps including:

sequestering pro-thrombin from plasma and converting the pro-thrombin to thrombin.

[Patent Application - 28182-pa - Page 18]

Claim 9 - Autologous thrombin which provides fast clotting for more than 15 minutes.

Claim 10 - A composition for extracting thrombin from plasma consisting essentially of:

Plasma;

Ethanol (ETOH);

CaCl<sub>2</sub>.

Claim 11 - The composition of claim 10 wherein ETOH is present at 13.6% and  $CaCl_2$  is present at .023 $\mu$ m both by volume.

Claim 12 - A method for preparing thrombin comprising:

obtaining plasma;

adding ETOH and CaCl2 to the plasma, forming a composition;

agitating the composition;

filtering the composition of particulate, thereby passing the thrombin through the filter.

Claim 13 - A manifold with an integrated filter for preparing thrombin from plasma, comprising:

a dock for a plasma syringe on the manifold;

a receptacle for a solution of CaCl<sub>2</sub> and ETOH and a dock on the manifold therefore;

a dock for a thrombin receiving syringe to receive the thrombin through the filter;

the integrated filter located on the manifold and just upstream the thrombin receiving syringe.

#### **ABSTRACT**

A sterile method for preparing stable thrombin component from a single donor's plasma in which the thrombin component is harvested simultaneously from the clotting and adhesive proteins component from the same donor plasma in less than one hour. The combined components provide an improved biological hemostatic agent and tissue sealant by virtue of its freedom from the risk of contaminating viruses or bacteria from allogenic human or bovine blood sources. The thrombin provides polymerization of the clotting and adhesive proteins in less than five seconds, and is sufficiently stable to provide that fast clotting over a six hour period. Further, the clotting times can be predictably lengthened by diluting the thrombin with saline.

#### UNITED STATES PATENT AND TRADEMARK OFFICE

**APPLICANT:** Coelho, P., et al.

**FOR:** Apparatus and Method of

Preparation of Stable, Long Term Thrombin from Plasma And Thrombin Formed Thereby


To: Commissioner of Patents and Trademarks Washington, DC 20231

## **LETTER TO THE DRAFTSMAN**

Subject to the Examiner's approval, kindly enter the enclosed twelve (12) sheets of formal drawing figures (comprised of figures 1 through 12) in place of the drawing figures as originally filed in the above-identified case.

Dated: November 9, 2000 Respectfully Submitted:

BERNHARD KRETEN Applicant's Attorney Telephone (916) 921-6181 Registration No.: 27,037






Fig. 2




Fig. 3







Fig. 4







LIFESPAN AND CLOTTING SPEED OF THROMBIN PROCESSED IN CONTAINERS OF DIFFERENT MATERIALS



ENRICHED THROMBIN FRACTION AS COMPARED TO THE ORIGINAL PLASMA REDUCTION IN CONTAMINATING PROTEINS FROM OPTIMIZED






**LIFESPAN OF THROMBIN PREPARATION** (DILUTED 1:1.5 FOR SLOW CLOTTING) **LIFESPAN (MIN) CONCENTRATIONS IN FINAL VOLUME** ETOH 13.6% CaCl<sub>2</sub> .023μm 

CLOT TIME (SEC)

TYPICAL CONVERSION/ACTIVATION PERIODS TO CONVERT OPTIMIZED, ENRICHED PROTHROMBIN FRACTION TO THROMBIN




**CONCENTRATIONS IN FINAL VOLUME** 

- ETOH 13.6% CaCl<sub>2</sub> .023μm

Fig. 11

BOVINE THROMBIN CONCENTRATION VS. CLOTTING TIME



#### **DECLARATION FOR PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled <u>Apparatus and Method of Preparation of Stable</u>, <u>Long Term Thrombin from Plasma and Thrombin Formed Thereby</u>, the specification of which:

Thereby, the specification of which:		
is attached hereto.  XX was filed on August 5, 1998 as Application Serial No.: 09/129,988  and was amended on: (if applicable).		
I hereby state that I have reviewed and understand the contents of the above identified specification including the claims, as amended by any amendment referred to above.		
I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37. (Code of Federal Regulations 1.56(a)).		
I hereby claim foreign priority benefits under Title 35, U.S. Code 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:		
Prior Foreign Application(s) Priority Claimed NO		
(Number) (Country) (Day/Month/Year)		
I hereby claim the benefit under Title 35, U.S. Code 120 of any U.S. application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior U.S. application in the manner provided by the first paragraph of Title 35, U.S. Code 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, 1.56(a), which occurred between the filing date of the prior application and the national or PCT international filing date of this application:		
(Application Serial No.) (Filing Date) (Status-patented, pending, abandoned)		
I hereby appoint BERNHARD KRETEN, Reg. No. 27,037; VICTOR J. GALLO, Reg. No. 41,768; DENNIS A. DEBOO, Reg. No. 42,471; to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.		
Address all telephone calls to: (916) 921-6181 Address all correspondence to 77 Cadillac Drive, Suite 245, Sacramento, California 95825		
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.		
Full Name of Inventor: Philip Henry Coelho Citizenship: United States		
Inventor's Signature 2006/98		
Residence: 121 Giotto Way, El Dorado Hills, California 95762		
Post Office Address: 121 Giotto Way, El Dorado Hills, California 95762		
Full Name of Inventor: Phil Kingsley Citizenship: United States		
Inventor's Signature: The back Date: 10/6/98		

Residence: 9560 Appalachian Drive, Sacramento, California 95827

Full Name of Inventor: <u>Jim Brausch</u>	Citizenship: <u>United States</u>
Inventor's Signature: James Bround	Date: 10-6-98
Residence: 6875 Villa Juarez Circle, Sacramento, Californ	nia 95828
Post Office Address: 6875 Villa Juarez Circle, Sacramen	to, California 95828
Full Name of Inventor: James H. Godsey	Citizenship: United States
Inventor's Signature: Janu H Godey	Date:/0-6-98
Residence: 101 Summer Shade Court, Folsom, California	95630
Post Office Address: 101 Summer Shade Court, Folsom,	California 95630
Full Name of Inventor: Gail Rock	Citizenship: Canadian
Inventor's Signature:	Date:
Residence: 270 Sandridge Road, Ottawa, Ontario, Canada	K1L 5A2
Post Office Address: 270 Sandridge Road, Ottawa, Ontari	io, Canada K1L 5A2

Full Name of Inventor: Jim Brausch	Citizenship: United States
Inventor's Signature:	Date:
Residence: 6875 Villa Juarez Circle, Sacramento, Californ	ia 95828
Post Office Address: 6875 Villa Juarez Circle, Sacrament	to, California 95828
Full Name of Inventor: James H. Godsey	Citizenship: United States
Inventor's Signature:	Date:
Residence: 101 Summer Shade Court, Folsom, California	95630
Post Office Address: 101 Summer Shade Court, Folsom.	California 95630
Full Name of Inventor: Gail Rock	Citizenship: Canadian
Inventor's Signature: Seul Rock	Date: 12 Oct 48
Residence: 270 Sandridge Road, Ottawa, Ontario, Canada	K1L 5A2
Post Office Address: 270 Sandridge Road, Ottawa, Ontari-	o, Canada K1L 5A2